Brind.

Analyst Ratings and Target Price Reports for Small-Cap Healthcare Companies

2 reports, 2 independent Updated Sat 00:00
No new developments lately
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MarketBeat published a comparison of two small-cap healthcare companies, Myriad Genetics and Applied DNA Sciences, based on revenue, earnings per share, and valuation. The report noted that Myriad Genetics has a consensus target price of $3.12, suggesting a potential downside of 24.64%. The companies were compared on various factors, including institutional ownership and stock price volatility.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The analysis suggests that analysts view Myriad Genetics as the more favorable of the two companies due to its stronger consensus rating and higher probable upside. The report also noted that Applied DNA Sciences has a beta of 0.63, indicating lower stock price volatility compared to Myriad Genetics' beta of 1.68.

From themarketsdaily.com

Who's involved

  • Myriad GeneticsSmall-cap American biotechnology company subject to analyst rating.
  • Applied DNA SciencesSmall-cap American high-technology company subject to analyst rating.
  • MarketBeatAmerican personal finance blog publishing comparative financial analysis.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Applied DNA SciencesSpeculative

    Applied DNA Sciences might face market price pressure due to unfavorable analyst comparisons in the published report.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped